Merlin Inhibitors in Acute Myeloid Leukemia: An Overview of 'Encouraging' Early Data

摘要

Following a panel discussion of menin inhibitors and other topics at a recent Around the Practice? program, moderator Naval G. Daver, MD, spoke with CancerNetwork? about how these new agents may affect the standard of care and improve outcomes for patients with acute myeloid leukemia (AML).Daver, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, also highlighted other standard and emerging treatment options for AML, including CD47-targeting antibodies and CD123-targeting antibody-drug conjugates (ADCs). He also emphasized the critical importance of multidisci-plinary care in the AML space.